High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years (original) (raw)
Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395–403. ArticlePubMed Google Scholar
Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86:1143–1150. ArticlePubMedCAS Google Scholar
Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–174. ArticlePubMedCAS Google Scholar
Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527. ArticlePubMed Google Scholar
Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–834. ArticlePubMedCAS Google Scholar
Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617–624. ArticlePubMedCAS Google Scholar
Brunetto MR, Giarin M, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B virus in course of chronic hepatitis. Proc Natl Acad Sci USA. 1991;88:4186–4190. ArticlePubMedCASPubMed Central Google Scholar
Naoumov NV, Schneider R, Grötzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology. 1992;102:538–543. PubMedCAS Google Scholar
Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–806. ArticlePubMedCAS Google Scholar
Lee CM, Ong GY, Lu SN, Changchien CS, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37:669–674. ArticlePubMedCAS Google Scholar
Ahn SH, Chan HL, Chen PJ, et al. Chronic hepatitis B: whom to treat and for how long? Proposition, challenges, and future directions. Hepatol Int. 2010;4:386–395. ArticlePubMedPubMed Central Google Scholar
van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut. 2003;52:420–424. ArticlePubMedPubMed Central Google Scholar
Kuo YH, Chen CH, Wang JH, et al. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75–81. ArticlePubMedCAS Google Scholar
Tseng TC, Liu CJ, Su TH, et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis. 2012;206:1521–1531. ArticlePubMed Google Scholar
Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283. ArticlePubMedPubMed Central Google Scholar
Chen CH, Hung CH, Lee CM, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 2007;133:1466–1474. ArticlePubMedCAS Google Scholar
Chen CH, Lee CM, Lu SN, et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol. 2005;43:6000–6006. ArticlePubMedCASPubMed Central Google Scholar
Chen CH, Lee CM, Lu SN, et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol. 2006;44:76–82. ArticlePubMedCAS Google Scholar
Chen CH, Lee CM, Hung CH, et al. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. Liver Int. 2007;27:806–815. ArticlePubMedCAS Google Scholar
Lee CM, Chen CH, Lu SN, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol. 2003;1:95–101. Google Scholar
Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol. 2009;104:1940–1946. ArticlePubMedCAS Google Scholar
Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415–421. ArticlePubMedCAS Google Scholar
Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for posttreatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut. 2003;52:1779–1783. ArticlePubMedCASPubMed Central Google Scholar
Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458–1465. ArticlePubMedCAS Google Scholar
Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756–1762. ArticlePubMedCAS Google Scholar
Chen CH, Lee CM, Wang JH, et al. Combination and evolution of HBV mutant strains in HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. Hepatol Int. 2013;7:477–488. ArticleCAS Google Scholar
Yeh CT, Hsu CW, Chen YH, et al. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol. 2009;45:114–118. ArticlePubMedCAS Google Scholar
Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273. ArticlePubMedCAS Google Scholar
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531. ArticlePubMedCAS Google Scholar
Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893. ArticlePubMedCAS Google Scholar